EU Cyber Resilience Act (CRA) for Medical Devices
End-to-end EU Cyber Resilience Act (Regulation 2024/2847) readiness for medical device manufacturers - essential cybersecurity requirements, vulnerability handling, conformity assessment, and ENISA reporting workflow - aligned with MDR/IVDR and your FDA cybersecurity program so one control set produces evidence for both.
250+ FDA submissions. no cybersecurity-related rejections to date.
- Senior team
- Fixed-fee
- Reviewer-ready
- Re-test included
- Free 30-min call
- No obligation
- Senior expert, not a sales rep
- Fixed-fee quote in 24 hours
- NDA available on request
Reviewer-ready deliverables in one engagement
Every eu cyber resilience act (cra) for medical devices engagement ships with the artifacts FDA reviewers expect to see - traceable, complete, and aligned with current guidance.
- CRA scoping: products with digital elements, important/critical class determination
- Annex I Part I essential cybersecurity requirements gap assessment
- Annex I Part II vulnerability handling process (24-hour ENISA notification)
- Conformity assessment route selection (self-assessment, EU-type, full QA)
- MDR/IVDR + CRA dual-track documentation crosswalk
- Technical documentation, EU declaration of conformity, and CE-mark file
EU Cyber Resilience Act (CRA) for Medical Devices FAQs
Filing in the U.S. and EU?
Most teams can run one cybersecurity evidence set and present it twice. Our EU MDR vs FDA cybersecurity crosswalk covers the narrative comparison: legal anchors, deliverables, disclosure clocks, and the IVDR differences. For the row-by-row control mapping, use mdccrosswalk.com, a free standards crosswalk we sponsor.
EU CRA readiness for connected medical devices.
End-to-end EU Cyber Resilience Act (Regulation 2024/2847) readiness for medical device manufacturers - essential cybersecurity requirements, vulnerability handling, conformity assessment, and ENISA reporting workflow - aligned with MDR/IVDR and your FDA cybersecurity program so one control set produces evidence for both.
